in

New drug combo shrinks tumors in most patients facing aggressive cancer type

new-drug-combo-shrinks-tumors-in-most-patients-facing-aggressive-cancer-type
New drug combo shrinks tumors in most patients facing aggressive cancer type

NEWYou can now listen to Fox News articles!

Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference.

The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase ½ trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel.

The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.

PANCREATIC CANCER PATIENT BEN SASSE SEES ‘MASSIVE’ TUMOR REDUCTION WITH EXPERIMENTAL NEW DRUG

Pancreatic cancer is notoriously difficult to treat because more than half of patients are diagnosed after the disease has already spread, research shows.

In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between 8 and 11 months.

man-taking-pill

Combining an experimental daily pill called daraxonrasib with standard chemotherapy shrank tumors or stopped cancer growth in 90.2% of patients with untreated, advanced pancreatic cancer. (iStock)

According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis.

In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans. Overall, the combination stopped tumor growth in 90.2% of participants.

FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS’ SURVIVAL RATES NEARLY DOUBLE

Patients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found.

“We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” study lead Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said in a press release.

woman sits at home while receiving chemo

Most side effects, including rash, diarrhea, fatigue and low blood cell counts, were manageable with standard care, and only 5% of patients stopped treatment due to daraxonrasib. (iStock)

More than 90% of pancreatic cancers are driven by a faulty gene called RAS, which allows tumors to keep growing. Daraxonrasib is designed to turn off that growth signal, something scientists long thought was impossible to fix with medication.

Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits.

CLICK HERE FOR MORE HEALTH STORIES

Side effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care.

Only 5% of patients stopped treatment because of side effects tied to daraxonrasib.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Researchers emphasized that the findings carry some limitations.

Because this was an early-phase, single-group study involving 61 people, all participants received the experimental combination. Without a direct comparison group of patients receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival.

medical scan of human pancreas

Researchers are now running a larger, randomized Phase 3 trial to directly compare the new treatment against standard chemotherapy. (iStock)

The findings also apply strictly to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers. Separate studies would be needed to test whether the combination works in those diseases.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

To determine whether these early findings translate into a durable survival benefit, researchers have launched a larger, randomized Phase 3 trial, called RASolute-303, which directly compares daraxonrasib — both on its own and combined with chemotherapy — against standard chemotherapy alone.

Khloe Quill is a lifestyle writer with Fox News Digital. She and the lifestyle team cover a range of story topics including food and drink, travel, and health. 

Leave a Reply

‘enough’:-protesters-decry-antisemitism-after-hunter-college-student-event-including-jewish-group-is-canceled

‘Enough’: Protesters decry antisemitism after Hunter College student event including Jewish group is canceled

alabama-woman-pleads-guilty-after-reportedly-using-smart-glasses-to-target-drug-trial-witnesses

Alabama woman pleads guilty after reportedly using smart glasses to target drug trial witnesses